Joint Steering Committee. Within ​ after the Effective Date, the Parties shall form a Joint Steering Committee (the “JSC”) to facilitate the transfer of information and coordinate processes related to the development, Regulatory Approval and Commercialization of the SYROS Products and the QIAGEN IVDs being the subject of this Agreement. The JSC shall be composed of ​ representatives appointed by each Party, at least ​ of which shall be different than members of the JPT. Each representative shall be appointed (and may be replaced at any time) by a Party upon prior written notice to the other Party. These representatives shall have appropriate experience, knowledge, and ongoing familiarity with the Projects in their then current phases.

The Joint Steering Committee shall comprise an equal number of representatives of EyePoint and of Imprimis, as determined by mutual agreement of the Parties. Initially, the Joint Steering Committee shall comprise one (1) C-suite executive of EyePoint as EyePoint’s representative and one (1) board member or C-suite executive of Imprimis as Imprimis’ representative. Each Party shall appoint its representative to the Joint Steering Committee prior to the first meeting thereof, and from time to time may substitute its representative with another C-suite executive decision maker of such Party, in its sole discretion, effective upon written notice to the other Party of such change, but shall use commercially reasonable efforts to maintain stability of Joint Steering Committee representation.

Joint Steering Committee. Within ​ following the Effective Date, the Parties shall establish a joint steering committee (the “Joint Steering Committee” or “JSC”) to oversee matters related to the Development, Manufacturing and Commercialization of the Products in the Territory, including Regulatory Strategy, marketing, reimbursement, sales and revenue targets, and scientific and market access matters.

Joint Steering Committee. Each Party hereby appoints the Chief Executive Officer of [[Cytokinetics:Organization]] and the Chairman of Ji Xing to serve on a joint steering committee (the “Joint Steering Committee” or the “JSC”) to manage the overall collaboration of the Parties under this Agreement. The JSC shall in particular: # review, discuss and approve the overall strategy for the Development of the Product in the Field in the Territory; # review and discuss the overall strategy for the Manufacture, Medical Affairs Activities and Commercialization of the Product in the Field in the Territory; # provide a forum for the discussion and coordination of the Parties’ activities under this Agreement; # direct and oversee the operation of the JDC, JCC and any other joint subcommittee established by JSC, including resolving any disputed matter of the JDC, JCC and other joint subcommittees; # establish other joint subcommittees as necessary or advisable to further the purpose of this Agreement; and # perform such other functions as expressly set forth in this Agreement or allocated to it by the Parties’ written agreement.

Joint Steering Committee. The Parties have established a JSC pursuant to the Collaboration Agreement which shall also oversee the activities of the Parties under this Agreement.

. Within ​ after the Effective Date, the Parties shall establish a cross-functional, joint steering committee (the “JSC”) composed of up to ​ senior representatives from each Party (provided that each Party has an equal number of representatives) that will oversee and manage the collaboration between the Parties with respect to each Research Program. The JSC may, from time to time, establish subcommittees and Working Groups as it deems necessary to further the purposes of this Agreement. Each Party shall appoint its respective representatives to the JSC from time to time, and may change its representatives, in its sole discretion, effective upon written notice to the other Party designating such change. The representatives from each Party shall have appropriate technical credentials, experience and knowledge pertaining to, and ongoing familiarity, with the Research and applicable Research Programs. ​

Joint Steering Committee. The Parties hereby establish a joint steering committee (the “JSC”) to oversee and coordinate Development and Commercialization in the Acer Territory and the Relief Territory, and to encourage and facilitate the ongoing cooperation and communication between the Parties regarding matters related to such activities.

Joint Steering Committee. The Parties have established a joint steering committee (“Joint Steering Committee”) to provide oversight and management of the activities undertaken under this Agreement that do not relate to [[Unknown Identifier]] (and [[Unknown Identifier]] shall not be subject to the Joint Steering Committee in any event). The Joint Steering Committee shall be composed of two (2) representatives of each Party who shall be appointed (and may be replaced at any time) by such Party on prior written notice to the other Party in accordance with this Agreement. At least one (1) representative of a Party on the Joint Steering Committee shall be a vice-president or more senior officer of such Party, and the representatives shall have relevant experience and expertise in research, development and commercialization of biopharmaceuticals.

The Parties shall establish a Joint Steering Committee within thirty (30) days after the Effective Date that will have the responsibility for the overall coordination and oversight of the Parties’ activities under this Agreement. As soon as practicable following the Effective Date (but in no event more than thirty (30) days following the Effective Date), each Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets ​ and an asterisk*, have been separately filed with the Securities and Exchange Commission.

Joint Steering Committee. The Parties have appointed a joint steering committee (“Joint Steering Committee”) pursuant to the BLA Agreement. Such Joint Steering Committee shall continue to perform its applicable functions in relation to this Agreement. The Joint Steering Committee shall meet once per calendar quarter, or at such other frequency as may be necessary and is mutually agreed by the Parties. Decisions of the Joint Steering Committee shall be made by consensus, with each Party having one (1) vote. In the event that a Joint Steering Committee cannot reach consensus with respect to a particular matter within its authority, such dispute shall be escalated to a senior executive of each of Customer and Lonza who shall confer in good faith on the resolution of the issue. Any final decision mutually agreed to by the senior executives shall be reduced to writing and signed by the Parties and shall then be conclusive and binding on the Parties. The Joint Steering Committee shall coordinate closely with the joint steering committee under the [[Unknown Identifier]] Development Agreement.